A Phase 2 interventional study of CP-690,550 and CP-690,550 in Crohn's Disease, sponsored by Pfizer. Completed at 75 sites in 17 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2017-10-16.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.
Among the 17 studies in Crohn Disease by Pfizer, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 9th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 11 interventional studies, 1,431 across the 5 observational. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Crohn Disease by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CP-690,550
Drug: CP-690,550
ORAL TABLET, TWICE DAILY
ORAL TABLETS, TWICE DAILY
Adjudicated Potential Cardiovascular Events
Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium 'Standardized Definitions for End Point Events in Cardiovascular Trials' published October 2010.
Time frame: From baseline to Week 52
Adjudicated Malignancy Events
Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.
Time frame: From baseline to Week 52
Adjudicated Hepatic Injury Events
Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of clinical, safety \& laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy's law case, recovery \& liver failure (all yes, no or undetermined).
Time frame: From baseline to Week 52
Adjudicated Opportunistic Infection Events
Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of SAE listings for serious infections coded to MedDRA infections \& infestations SOC \&/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research \& Treatment of Cancer/Invasive Fungal Infections Cooperative Group \& the National Institute of Allergy \& Infectious Diseases Mycoses Study Group \[EORTC/MSG\] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial \& parasitic infections \& vaccine dissemination) \& special interest infections (actinomycosis, Legionella \& mononucleosis-like toxoplasmosis).
Time frame: From baseline to Week 52
Adjudicated Gastrointestinal (GI) Perforation Events
Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.
Time frame: From baseline to Week 52
Adjudicated Interstitial Lung Disease (ILD) Events
Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety \& laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).
Time frame: From baseline to Week 52
Percentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (\<) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.
Time frame: Week 48
Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.
Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.
Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Time to Relapse Among Participants in Clinical Remission at Baseline
Relapse was defined as an increase in CDAI of more than (\>) 100 points from the baseline and an absolute CDAI score of \>220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves. n = number of participants remaining at risk.
Time frame: From baseline to Week 52
Observed CDAI Score by Week
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.
Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Change From Baseline Observed CDAI Score by Week
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.
Time frame: Weeks 8, 16, 24, 36, 48 and 52/follow-up
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline
Steroid-free clinical remission at Week 48 was a CDAI \<150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Time frame: Week 48
Corticosteroid Use Over Time
Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.
Time frame: Weeks 8, 16, 24, 36 and 48
Percentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit
There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.
Time frame: From baseline to Week 48
Observed Change From Baseline in Fecal Calprotectin by Week
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.
Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Observed Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.
Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit
The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.
Time frame: Baseline and Week 48/early termination (ET)
Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.
Time frame: Baseline and Week 48/ET
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.
Time frame: Week 48/ET
Percentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category
The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.
Time frame: Week 48/ET visit
Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit
The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.
Time frame: Baseline and Week 48/ET visit
Change From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit
The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.
Time frame: Baseline and Week 48/ET visit
EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.
Time frame: Baseline and Week 48/ET visit
Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.
Time frame: Baseline and Week 48/ET visit
EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.
Time frame: Baseline and Week 48/ET visit
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline and Week 48/ET visit
Percentage of Participants Hospitalized Due to Crohn's Disease
The number of participants hospitalized due to Crohn's disease were recorded at every study visit.
Time frame: From baseline to Week 52/follow-up
Length of Hospitalizations Due to Crohn's Disease
The length of hospitalizations due to Crohn's disease were recorded at every study visit.
Time frame: From baseline to Week 52/follow-up
This study was conducted in participants who completed the 26-week maintenance treatment of Study A3921084 or who withdrew early due to A3921084 study treatment failure according to prespecified criteria.
| Milestone | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Started | 62 | 88 |
| Completed | 43 | 45 |
| Not completed | 19 | 43 |
| Withdrew: Did not meet entrance criteria | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Adverse event related to study drug | 2 | 5 |
| Withdrew: Insufficient clinical response | 6 | 27 |
| Withdrew: Adverse event not related to study drug | 1 | 5 |
Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium 'Standardized Definitions for End Point Events in Cardiovascular Trials' published October 2010.
| Number of events meeting criteria | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Adjudicated Potential Cardiovascular Events | — | 0 |
Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.
| Number of events meeting criteria | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Adjudicated Malignancy Events | 0 | 1 |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (\<) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.
| Percent | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Clinical remission (n=33, 36) | 87.88 (71.80 to 96.60) | 55.56 (38.10 to 72.06) |
| Sustained clinical remission (n=32, 35) | 75.00 (56.60 to 88.54) | 34.29 (19.13 to 52.21) |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Clinical remission: Baseline (n=61, 4) | 100.00 (94.13 to 100.00) | 100.00 (39.76 to 100.00) |
| Clinical remission: Week 8 (n=53, 4) | 75.47 (61.72 to 86.24) | 50.00 (6.76 to 93.24) |
| Clinical remission: Week 16 (n=52, 4) | 84.62 (71.92 to 93.12) | 75.00 (19.41 to 99.37) |
| Clinical remission: Week 24 (n=48, 4) | 85.42 (72.24 to 93.93) | 25.00 (0.63 to 80.59) |
| Clinical remission: Week 36 (n=40, 3) | 92.50 (79.61 to 98.43) | 33.33 (0.84 to 90.57) |
| Clinical remission: Week 48 (n=32, 3) | 87.50 (71.01 to 96.49) | 100.00 (29.24 to 100.00) |
| Clinical remission: Week 52/follow-up (n=37, 3) | 64.86 (47.46 to 79.79) | 33.33 (0.84 to 90.57) |
| Sustained clinical remission (n=31, 3) | 77.42 (58.90 to 90.41) | 33.33 (0.84 to 90.57) |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Clinical remission: Baseline (n=62, 23) | 98.39 (91.34 to 99.96) | 17.39 (4.95 to 38.78) |
| Clinical remission: Week 8 (n=54, 20) | 75.93 (62.36 to 86.51) | 35.00 (15.39 to 59.22) |
| Clinical remission: Week 16 (n=53, 19) | 84.91 (72.41 to 93.25) | 36.84 (16.29 to 61.64) |
| Clinical remission: Week 24 (n=49, 16) | 83.67 (70.34 to 92.68) | 43.75 (19.75 to 70.12) |
| Clinical remission: Week 36 (n=41, 13) | 90.24 (76.87 to 97.28) | 38.46 (13.86 to 68.42) |
| Clinical remission: Week 48 (n=33, 10) | 87.88 (71.80 to 96.60) | 50.00 (18.71 to 81.29) |
| Clinical remission: Week 52/follow-up (n=38, 12) | 65.79 (48.65 to 80.37) | 41.67 (15.17 to 72.33) |
| Sustained clinical remission (n=32, 10) | 75.00 (56.60 to 88.54) | 30.00 (6.67 to 62.25) |
Relapse was defined as an increase in CDAI of more than (\>) 100 points from the baseline and an absolute CDAI score of \>220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves. n = number of participants remaining at risk.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Week 8 (n=55, 4) | 6.78 (3.38 to 11.78) | NA (NA to NA) |
| Week 16 (n=51, 3) | 11.86 (7.15 to 17.87) | 25.00 (4.56 to 53.66) |
| Week 24 (n=46, 3) | 15.46 (9.98 to 22.05) | 25.00 (4.56 to 53.66) |
| Week 36 (n=38, 3) | 21.42 (14.82 to 28.83) | 25.00 (4.56 to 53.66) |
| Week 48 (n=7, 0) | 24.69 (17.21 to 32.89) | NA (NA to NA) |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Baseline (n=62, 88) | 77.13 ± 43.22 | 291.19 ± 95.78 |
| Week 8 (n=54, 75) | 105.39 ± 75.82 | 176.96 ± 82.39 |
| Week 16 (n=53, 66) | 86.58 ± 65.23 | 178.94 ± 72.25 |
| Week 24 (n=49, 59) | 85.12 ± 56.67 | 163.66 ± 79.73 |
| Week 36 (n=41, 48) | 73.34 ± 59.52 | 158.67 ± 89.15 |
| Week 48 (n=33, 36) | 73.91 ± 70.23 | 154.11 ± 71.47 |
| Week 52/Follow-up (n=38, 43) | 129.32 ± 114.82 | 180.65 ± 98.80 |
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Week 8 (n=54, 75) | 26.96 ± 62.68 | -114.31 ± 112.44 |
| Week 16 (n=53, 66) | 11.72 ± 52.25 | -112.02 ± 111.09 |
| Week 24 (n=49, 59) | 6.33 ± 44.48 | -122.69 ± 117.65 |
| Week 36 (n=41, 48) | -10.78 ± 40.35 | -139.81 ± 126.18 |
| Week 48 (n=33, 36) | -4.79 ± 60.09 | -121.94 ± 129.21 |
| Week 52/Follow-up (n=38, 43) | 47.66 ± 109.73 | -107.42 ± 119.05 |
Steroid-free clinical remission at Week 48 was a CDAI \<150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline | 50.00 (1.26 to 98.74) | 9.09 (0.23 to 41.28) |
Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Baseline | 1.61 | 20.45 |
| Week 8 | 4.84 | 21.59 |
| Week 16 | 4.84 | 13.64 |
| Week 24 | 4.84 | 12.50 |
| Week 36 | 3.23 | 10.23 |
| Week 48 | 1.61 | 7.95 |
There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Baseline | 0 (0.00 to 5.78) | 0 (0.00 to 4.11) |
| Week 8 | 25.81 (15.53 to 38.50) | 0 (0.00 to 4.11) |
| Week 16 | 6.45 (1.79 to 15.70) | 0 (0.00 to 4.11) |
| Week 24 | 3.23 (0.39 to 11.71) | 2.27 (0.28 to 7.97) |
| Week 36 | 0 (0.00 to 5.78) | 1.14 (0.03 to 6.17) |
| Week 48 | 0 (0.00 to 5.78) | 0 (0.00 to 4.11) |
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.
| mg per kilogram (mg/kg) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Week 8 (n=53, 71) | -105.51 ± 436.41 | -102.82 ± 310.10 |
| Week 16 (n=54, 64) | -144.65 ± 423.20 | -35.28 ± 718.82 |
| Week 24 (n=49, 55) | -120.49 ± 511.49 | -130.68 ± 337.23 |
| Week 36 (n=41, 42) | -169.92 ± 354.30 | -133.82 ± 364.51 |
| Week 48 (n=37, 38) | -189.61 ± 462.61 | -123.87 ± 376.70 |
| Week 52/Follow-up (n=48, 57) | -51.33 ± 453.73 | -109.23 ± 389.54 |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.
| mg per liter (mg/L) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Week 8 (n=61, 82) | -0.44 ± 14.78 | -4.81 ± 26.76 |
| Week 16 (n=58, 72) | -2.46 ± 14.54 | -7.96 ± 25.11 |
| Week 24 (n=54, 61) | -2.76 ± 17.59 | -9.26 ± 30.20 |
| Week 36 (n=46, 51) | -4.42 ± 22.29 | -12.09 ± 30.61 |
| Week 48 (n=43, 44) | -4.55 ± 17.81 | -11.45 ± 31.30 |
| Week 52/Follow-up (n=54, 71) | 3.86 ± 21.57 | -4.72 ± 31.34 |
The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| IBDQ Total Score, Baseline (n=62, 87) | 187.23 ± 20.38 | 127.32 ± 34.17 |
| IBDQ Total Score, Week 48/ET (n=57, 83) | 179.26 ± 29.89 | 144.42 ± 42.16 |
| Bowel Function Score, Baseline (n=62, 87) | 58.56 ± 6.86 | 40.71 ± 9.90 |
| Bowel Function Score, Week 48/ET (n=57, 83) | 55.70 ± 9.82 | 46.70 ± 12.38 |
| Emotional Status Score, Baseline (n=62, 87) | 69.68 ± 8.58 | 48.61 ± 14.42 |
| Emotional Status Score, Week 48/ET (n=57, 83) | 66.98 ± 12.27 | 53.19 ± 17.32 |
| Systemic Symptoms Score, Baseline (n=62, 87) | 26.95 ± 5.36 | 17.20 ± 5.55 |
| Systemic Symptoms Score, Week 48/ET (n=57, 83) | 25.82 ± 6.28 | 20.35 ± 7.07 |
| Social Function Score, Baseline (n=62, 87) | 32.03 ± 3.59 | 20.80 ± 8.96 |
| Social Function Score, Week 48/ET (n=57, 83) | 30.75 ± 5.17 | 24.18 ± 8.98 |
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| IBDQ Total Score, Week 48/ET | -7.98 ± 24.93 | 18.84 ± 40.45 |
| Bowel Function Score, Week 48/ET | -2.72 ± 8.30 | 6.37 ± 12.41 |
| Emotional Status Score, Week 48/ET | -3.07 ± 10.48 | 5.36 ± 15.00 |
| Systemic Symptoms Score, Week 48/ET | -1.00 ± 4.83 | 3.45 ± 7.43 |
| Social Function Score, Week 48/ET | -1.19 ± 4.24 | 3.66 ± 8.89 |
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit | 70.18 (56.60 to 81.57) | 31.33 (21.59 to 42.44) |
The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| PSA: Extremely dissatisfied | 0 | 0 |
| PSA: Dissatisfied | 0 | 8.7 |
| PSA: Neither satisfied nor dissatisfied | 0 | 17.4 |
| PSA: Satisfied | 33.3 | 41.3 |
| PSA: Extremely satisfied | 66.7 | 32.6 |
| PPTA: Injectable prescription medicines | 40.5 | 32.6 |
| PPTA: Prescription medicines taken by mouth | 45.2 | 43.5 |
| PPTA: Surgery | 2.4 | 0 |
| PPTA: Prescription medicines & surgery | 7.1 | 13.0 |
| PPTA: No treatment | 4.8 | 10.9 |
| PPA: Definitely prefer the drug I am receiving now | 88.1 | 56.5 |
| PPA: Slight preference for drug I'm receiving now | 4.8 | 21.7 |
| PPA: I have no preference either way | 7.1 | 17.4 |
| PPA: Slight preference for previous treatment | 0 | 4.3 |
| PPA: No, I definitely prefer my previous treatment | 0 | 0 |
| PWA: Would definitely want to use same drug again | 83.3 | 60.9 |
| PWA: Might want to use the same drug again | 14.3 | 23.9 |
| PWA: I am not sure | 2.4 | 10.9 |
| PWA: Might not want to use same drug again | 0 | 0 |
| PWA: Definitely not want to use same drug again | 0 | 4.3 |
The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Physical component score, Baseline (n=62, 86) | 50.15 ± 6.73 | 37.80 ± 9.53 |
| Physical component score, Week 48/ET (n=57, 83) | 48.43 ± 8.22 | 41.87 ± 10.06 |
| Mental Component Score, Baseline (n=62, 86) | 50.25 ± 9.11 | 37.17 ± 11.94 |
| Mental Component Score, Week 48/ET (n=57, 83) | 48.79 ± 10.64 | 39.60 ± 12.87 |
| Physical Functioning Domain, Baseline (n=62, 86) | 53.35 ± 5.50 | 43.50 ± 10.37 |
| Physical Functioning Domain, Week 48/ET (n=57, 83) | 51.40 ± 8.59 | 46.81 ± 10.22 |
| Role Physical Domain, Baseline (n=62, 86) | 50.97 ± 8.22 | 35.93 ± 11.30 |
| Role Physical Domain, Week 48/ET (n=57, 83) | 49.38 ± 8.78 | 40.04 ± 12.99 |
| Bodily Pain Domain, Baseline (n=62, 87) | 51.32 ± 8.55 | 35.31 ± 9.14 |
| Bodily Pain Domain, Week 48/ET (n=57, 83) | 49.57 ± 10.30 | 41.04 ± 12.69 |
| General Health Domain, Baseline (n=62, 87) | 41.60 ± 9.51 | 31.74 ± 8.41 |
| General Health Domain, Week 48/ET (n=57, 83) | 40.39 ± 10.08 | 33.45 ± 10.16 |
| Vitality Domain, Baseline (n=62, 87) | 52.78 ± 10.68 | 36.92 ± 9.88 |
| Vitality Domain, Week 48/ET (n=57, 83) | 51.06 ± 11.38 | 41.03 ± 12.38 |
| Social Functioning Domain, Baseline (n=62, 87) | 51.81 ± 7.21 | 36.38 ± 12.29 |
| Social Functioning Domain, Week 48/ET (n=57, 83) | 49.42 ± 9.64 | 39.82 ± 13.39 |
| Role Emotional Domain, Baseline (n=62, 86) | 50.12 ± 8.85 | 38.55 ± 12.73 |
| Role Emotional Domain, Week 48/ET (n=57, 83) | 47.97 ± 10.78 | 41.13 ± 13.15 |
| Mental Health Domain, Baseline (n=62, 87) | 49.89 ± 9.84 | 37.61 ± 11.98 |
| Mental Health Domain, Week 48/ET (n=57, 83) | 49.24 ± 10.27 | 40.13 ± 12.52 |
The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Physical component score, Week 48/ET (n=57, 83) | -1.47 ± 7.17 | 4.47 ± 11.06 |
| Mental Component Score, Week 48/ET (n=57, 83) | -1.88 ± 9.05 | 3.07 ± 11.53 |
| Physical Functioning Domain, Week 48/ET (n=57, 83) | -1.80 ± 7.50 | 3.49 ± 10.74 |
| Role Physical Domain, Week 48/ET (n=57, 83) | -1.38 ± 7.87 | 4.60 ± 12.62 |
| Bodily Pain Domain, Week 48/ET (n=57, 83) | -1.60 ± 7.90 | 6.15 ± 12.92 |
| General Health Domain, Week 48/ET (n=57, 83) | -1.42 ± 10.00 | 2.25 ± 7.99 |
| Vitality Domain, Week 48/ET (n=57, 83) | -1.63 ± 10.39 | 4.47 ± 12.16 |
| Social Functioning Domain, Week 48/ET (n=57, 83) | -2.92 ± 9.09 | 3.69 ± 13.46 |
| Role Emotional Domain, Week 48/ET (n=57, 82) | -2.26 ± 10.29 | 3.28 ± 11.38 |
| Mental Health Domain, Week 48/ET (n=57, 83) | -1.02 ± 8.63 | 2.87 ± 11.72 |
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Utility Score, Baseline (n=62, 85) | 0.85 ± 0.21 | 0.57 ± 0.28 |
| Utility Score, Week 48/ET (n=57, 83) | 0.84 ± 0.16 | 0.66 ± 0.31 |
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit | -0.02 ± 0.21 | 0.10 ± 0.36 |
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.
| mm | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| VAS Score, Baseline (n=62, 86) | 77.98 ± 16.18 | 48.60 ± 19.21 |
| VAS Score, Week 48/ET (n=57, 83) | 73.40 ± 18.54 | 57.60 ± 24.60 |
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
| mm | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit | -3.79 ± 20.56 | 10.16 ± 26.57 |
The number of participants hospitalized due to Crohn's disease were recorded at every study visit.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Percentage of Participants Hospitalized Due to Crohn's Disease | 11.3 | 15.9 |
Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of clinical, safety \& laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy's law case, recovery \& liver failure (all yes, no or undetermined).
| Number of events meeting criteria | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Adjudicated Hepatic Injury Events | — | 0 |
Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of SAE listings for serious infections coded to MedDRA infections \& infestations SOC \&/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research \& Treatment of Cancer/Invasive Fungal Infections Cooperative Group \& the National Institute of Allergy \& Infectious Diseases Mycoses Study Group \[EORTC/MSG\] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial \& parasitic infections \& vaccine dissemination) \& special interest infections (actinomycosis, Legionella \& mononucleosis-like toxoplasmosis).
| Number of events meeting criteria | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Adjudicated Opportunistic Infection Events | 1 | 1 |
Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.
| Number of events meeting criteria | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Adjudicated Gastrointestinal (GI) Perforation Events | — | 2 |
Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety \& laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).
No measurements were reported for this outcome.
The length of hospitalizations due to Crohn's disease were recorded at every study visit.
| Percentage of participnats | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| <3 days | 1.6 | 2.3 |
| 3 to 6 days | 6.5 | 10.2 |
| 7 to 10 days | 0 | 3.4 |
| > 10 days | 0 | 3.4 |
Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5 mg BID | — | 5/62 (8.1%) | 42/62 (67.7%) |
| Tofacitinib 10 mg BID | — | 14/88 (15.9%) | 58/88 (65.9%) |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 3/62 | 7/88 |
| Small intestinal obstructionGastrointestinal disorders | 0/62 | 2/88 |
| Colon dysplasiaGastrointestinal disorders | 1/62 | 0/88 |
| Chest painGeneral disorders | 1/62 | 0/88 |
| Influenza like illnessGeneral disorders | 1/62 | 0/88 |
| Diarrhoea infectiousInfections and infestations | 1/62 | 0/88 |
| PyelonephritisInfections and infestations | 1/62 | 0/88 |
| Acute kidney injuryRenal and urinary disorders | 1/62 | 0/88 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/62 | 0/88 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/62 | 0/88 |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 19/62 | 11/88 |
| NasopharyngitisInfections and infestations | 8/62 | 7/88 |
| Urinary tract infectionInfections and infestations | 8/62 | 7/88 |
| Abdominal painGastrointestinal disorders | 7/62 | 7/88 |
| GastroenteritisInfections and infestations | 7/62 | 2/88 |
| NauseaGastrointestinal disorders | 2/62 | 9/88 |
| influenzaInfections and infestations | 5/62 | 8/88 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/62 | 8/88 |
| VomitingGastrointestinal disorders | 1/62 | 6/88 |
| PyrexiaGeneral disorders | 1/62 | 6/88 |
The safety analysis set (SAS) consisted of all participants enrolled in this open label (OL) extension study who received at least 1 dose of study medication.
| Age, Continuous(Years) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|
| Mean | 41.0 ± 12.6 | 38.2 ± 11.6 | 39.4 ± 12.1 |
| Sex: Female, Male(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|
| Female | 30 | 41 | 71 |
| Male | 32 | 47 | 79 |
Ran from Apr 2012 to primary completion in Jul 2016, 51 months.
Results were first posted in Oct 2017, 1 year 3 months after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 51 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib